Brokers Issue Forecasts for Thermo Fisher Scientific Inc’s Q1 2018 Earnings (TMO)

Thermo Fisher Scientific Inc (NYSE:TMO) – Investment analysts at Jefferies Group dropped their Q1 2018 earnings per share estimates for shares of Thermo Fisher Scientific in a research note issued to investors on Thursday. Jefferies Group analyst B. Couillard now forecasts that the medical research company will post earnings of $2.34 per share for the quarter, down from their previous forecast of $2.35. Jefferies Group currently has a “Hold” rating and a $195.00 target price on the stock. Jefferies Group also issued estimates for Thermo Fisher Scientific’s Q3 2018 earnings at $2.61 EPS.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The company had revenue of $5.12 billion for the quarter, compared to analyst estimates of $5.03 billion. During the same period in the prior year, the company posted $2.03 EPS. Thermo Fisher Scientific’s quarterly revenue was up 13.9% on a year-over-year basis.

COPYRIGHT VIOLATION NOTICE: This story was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://ledgergazette.com/2017/11/13/brokers-issue-forecasts-for-thermo-fisher-scientific-incs-q1-2018-earnings-tmo.html.

Other equities analysts have also issued reports about the company. Zacks Investment Research lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Monday, September 18th. Bank of America Corporation reaffirmed a “buy” rating and issued a $210.00 target price (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Friday, July 21st. Cleveland Research raised Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research report on Thursday, July 20th. BidaskClub lowered Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Finally, Barclays PLC reaffirmed an “overweight” rating and issued a $215.00 target price (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Monday, September 25th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $205.71.

Thermo Fisher Scientific (NYSE TMO) opened at $186.18 on Monday. Thermo Fisher Scientific has a 52-week low of $139.07 and a 52-week high of $201.20. The stock has a market capitalization of $74,657.32, a P/E ratio of 20.46, a price-to-earnings-growth ratio of 1.71 and a beta of 1.08. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Zeke Capital Advisors LLC grew its stake in Thermo Fisher Scientific by 95.3% during the 3rd quarter. Zeke Capital Advisors LLC now owns 6,812 shares of the medical research company’s stock worth $1,289,000 after buying an additional 3,324 shares during the last quarter. Amalgamated Bank grew its stake in Thermo Fisher Scientific by 4.3% during the 3rd quarter. Amalgamated Bank now owns 46,864 shares of the medical research company’s stock worth $8,867,000 after buying an additional 1,943 shares during the last quarter. Iberiabank Corp grew its stake in Thermo Fisher Scientific by 342.9% during the 3rd quarter. Iberiabank Corp now owns 13,067 shares of the medical research company’s stock worth $2,506,000 after buying an additional 10,117 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in Thermo Fisher Scientific by 12.0% during the 3rd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 32,548 shares of the medical research company’s stock worth $6,158,000 after buying an additional 3,483 shares during the last quarter. Finally, Trexquant Investment LP grew its stake in Thermo Fisher Scientific by 18.3% during the 3rd quarter. Trexquant Investment LP now owns 8,340 shares of the medical research company’s stock worth $1,578,000 after buying an additional 1,289 shares during the last quarter. Hedge funds and other institutional investors own 83.78% of the company’s stock.

In related news, VP Peter E. Hornstra sold 3,894 shares of the company’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $185.18, for a total transaction of $721,090.92. Following the completion of the transaction, the vice president now directly owns 19,751 shares in the company, valued at approximately $3,657,490.18. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Jim P. Manzi sold 1,000 shares of the company’s stock in a transaction on Thursday, August 17th. The stock was sold at an average price of $175.20, for a total value of $175,200.00. Following the transaction, the director now owns 38,757 shares of the company’s stock, valued at $6,790,226.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 22,738 shares of company stock valued at $4,021,512. 0.49% of the stock is owned by company insiders.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be paid a dividend of $0.15 per share. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $0.60 dividend on an annualized basis and a yield of 0.32%. Thermo Fisher Scientific’s payout ratio is currently 10.19%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Earnings History and Estimates for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply